Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib

Introduction of targeted therapy in the treatment of metastatic cutaneous malignant melanoma (CMM) has improved clinical outcome during the last years. However, only in a subset of the CMM patients, this will lead to long-term effects. CEBPB is a transcription factor that has been implicated in vari...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Melanoma Res
Main Authors: Vidarsdottir, Linda, Fernandes, Rita Valador, Zachariadis, Vasilios, Das, Ishani, Edsbäcker, Elin, Sigvaldadottir, Ingibjorg, Azimi, Alireza, Höiom, Veronica, Hansson, Johan, Grandér, Dan, Egyházi Brage, Suzanne, Pokrovskaja Tamm, Katja
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2020
Assuntos:
Original Articles: Basic Science
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7469874/
https://ncbi.nlm.nih.gov/pubmed/32467529
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CMR.0000000000000675
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados